hGHRH(1-37)OH vs Anamorelin
Head-to-head comparison of hGHRH(1-37)OH (Human growth hormone-releasing factor (1-37) hydroxyl) and Anamorelin (Anamorelin hydrochloride (ONO-7643)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | hGHRH(1-37)OH | Anamorelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| Full Name | Human growth hormone-releasing factor (1-37) hydroxyl | Anamorelin hydrochloride (ONO-7643) |
| Molecular Weight | N/A | N/A |
| Half-Life | 5-20 minutes | about 9 hours |
| Amino Acids | 37 | N/A |
| Typical Dose | 1-2 mcg/kg | 50 mg/day |
| Route | Subcutaneous/IV | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 60 | 95 |
| Research Status | Clinical Research | Clinical |
hGHRH(1-37)OH Benefits
- ✓GH release studies
- ✓minimal-sequence mapping
- ✓receptor pharmacology
- ✓peptide stability research
Anamorelin Benefits
- ✓stimulates appetite
- ✓raises IGF-1
- ✓may support weight gain
- ✓oral dosing
hGHRH(1-37)OH Dosing
1-2 mcg/kg SC or IV bolus|acute stimulation with serial GH assays|short-course research administration with biomarker monitoring
Anamorelin Dosing
50 mg orally once daily|often studied with food or per protocol|track weight, appetite, and glucose markers
hGHRH(1-37)OH Side Effects
- ⚠flushing
- ⚠headache
- ⚠transient fatigue
Anamorelin Side Effects
- ⚠hyperglycemia
- ⚠peripheral edema
- ⚠constipation or nausea
Research Overview
hGHRH(1-37)OH
Human GHRF(1-37)OH has appeared in studies examining how loss of C-terminal residues affects biological activity at the GHRH receptor. It is often used alongside other fragments to define structure-activity relationships within the GHRH family.
Anamorelin
Trials in cachexia populations showed increased appetite and modest gains in body weight and IGF-1. Regulatory progress has varied by region, but it remains a well-studied ghrelin agonist in the GH space.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.